MedWatch

Novo Nordisk recruits 500 people for Alzheimer's trial

Alzheimer’s has been called the graveyard of the pharmaceutical industry, and many companies have failed within the indication. Still, signs indicate that Novo Nordisk has a chance of success with its GLP-1 approach, and Lundbeck’s head of R&D says there’s ”relatively strong reasoning behind it.”

Photo: Tidsvilde Stine/Ritzau Scanpix

The world’s biggest pharmaceutical firms have been trying for decades. Danish Lundbeck is having a go, and recently, Novo Nordisk threw its hat in the ring.

All in the name of trying to solve one of the brain’s biggest mysteries: Alzheimer’s disease.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs